

Research

Open Access

A discrete Single Delay Model for the Intra-Venous Glucose Tolerance Test

Simona Panunzi*¹, Pasquale Palumbo² and Andrea De Gaetano¹

Address: ¹CNR-IASI BioMatLab, Largo A. Gemelli 8 – 00168 Rome, Italy. and ²CNR-IASI, Viale A. Manzoni 30 – 00185 Rome, Italy.

Email: Simona Panunzi* - simona.panunzi@biomatematica.it; Pasquale Palumbo - palumbo@iasi.rm.cnr.it; Andrea De Gaetano - andrea.degaetano@biomatematica.it

* Corresponding author

Published: 12 September 2007

Received: 5 April 2007

Theoretical Biology and Medical Modelling 2007, **4**:35 doi:10.1186/1742-4682-4-35

Accepted: 12 September 2007

This article is available from: <http://www.tbiomed.com/content/4/1/35>

© 2007 Panunzi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Due to the increasing importance of identifying insulin resistance, a need exists to have a reliable mathematical model representing the glucose/insulin control system. Such a model should be simple enough to allow precise estimation of insulin sensitivity on a single patient, yet exhibit stable dynamics and reproduce accepted physiological behavior.

Results: A new, discrete Single Delay Model (SDM) of the glucose/insulin system is proposed, applicable to Intra-Venous Glucose Tolerance Tests (IVGTTs) as well as to multiple injection and infusion schemes, which is fitted to both glucose and insulin observations simultaneously. The SDM is stable around baseline equilibrium values and has positive bounded solutions at all times. Applying a similar definition as for the Minimal Model (MM) S_I index, insulin sensitivity is directly represented by the free parameter K_{xgl} of the SDM.

In order to assess the reliability of Insulin Sensitivity determinations, both SDM and MM have been fitted to 40 IVGTTs from healthy volunteers. Precision of all parameter estimates is better with the SDM: 40 out of 40 subjects showed identifiable ($CV < 52\%$) K_{xgl} from the SDM, 20 out of 40 having identifiable S_I from the MM. K_{xgl} correlates well with the inverse of the HOMA-IR index, while S_I correlates only when excluding five subjects with extreme S_I values. With the exception of these five subjects, the SDM and MM derived indices correlate very well ($r = 0.93$).

Conclusion: The SDM is theoretically sound and practically robust, and can routinely be considered for the determination of insulin sensitivity from the IVGTT. Free software for estimating the SDM parameters is available.

Background

The measurement of insulin sensitivity in humans from a relatively non-invasive test procedure is being felt as a pressing need, heightened in particular by the increase in the social cost of obesity-related dysmetabolic diseases [1-8]. Two experimental procedures are in general use for the estimation of insulin sensitivity: the Intra-Venous Glucose

Tolerance Test (IVGTT), often modeled by means of the so-called Minimal Model (MM) [9,10], and the Euglycemic Hyperinsulinemic Clamp (EHC) [11]. The EHC is often considered the "gold standard" for the determination of insulin resistance. However, the standard IVGTT is simpler to perform, carries no significant associated risk and delivers potentially richer information content. The diffi-

culty with using the IVGTT is its interpretation, for which it is necessary to apply a mathematical model of the status of the negative feedback regulation of glucose and insulin on each other in the studied experimental subject.

Due to its relatively simple structure and to its great clinical importance, the glucose/insulin system has been the object of repeated mathematical modeling attempts [12-23,23-30]. The mere fact that several models have been proposed shows that mathematical, statistical and physiological considerations have to be carefully integrated when attempting to represent the glucose/insulin system. In modeling the IVGTT, we require a reasonably simple model, with as few parameters to be estimated as practicable, and with a qualitative behavior consistent with physiology. Further, the model formulation, while applicable to the standard IVGTT, should logically and easily extend to model other often envisaged experimental procedures, like repeated glucose boli, or infusions. A simple, discrete Single Delay Model ("the discrete SDM") of both feedback control arms of the glucose-insulin system during an IVGTT has already been validated as far as its formal properties are concerned [31,32].

The present work has three main goals. The first goal is to present the physiological assumptions underlying the new model, from which an insulin sensitivity index, consistent with the currently employed insulin sensitivity index from the Minimal Model, can be derived. The second goal is to discuss in general the inconsistent results obtained by means of the common procedure of using observed insulinemias for the estimation of the glucose kinetics and then using observed glycemias for the estimation of insulin kinetics (instead of performing a single optimization on both feedback control arms of the glucose/insulin system). The third goal is finally to study comparatively the indices of Insulin sensitivity which are obtained from the newly proposed SDM and from the Minimal Model in its standard formulation (two equations for glycemia, driven by interpolated observed insulinemias), on a sample of IVGTT's from 40 healthy volunteers.

Methods

Experimental protocol

Data from 40 healthy volunteers (18 males and 22 females, average anthropometric characteristics reported in Table 1), who had been previously studied in several

protocols at the Catholic University Department of Metabolic Diseases were analyzed. All subjects had negative family and personal histories for Diabetes Mellitus and other endocrine diseases, were on no medications, had no current illness and had maintained a constant body weight for the six months preceding each study. For the three days preceding the study each subject followed a standard composition diet (55% carbohydrate, 30% fat, 15% protein) ad libitum with at least 250 g carbohydrates per day. Written informed consent was obtained in all cases; all original study protocols were conducted according to the Declaration of Helsinki and along the guidelines of the institutional review board of the Catholic University School of Medicine, Rome, Italy.

Each study was performed at 8:00 AM, after an overnight fast, with the subject supine in a quiet room with constant temperature of 22–24 °C. Bilateral polyethylene IV cannulas were inserted into antecubital veins. The standard IVGTT was employed (without either Tolbutamide or insulin injections)[9]: at time 0 (0') a 33% glucose solution (0.33 g Glucose/kg Body Weight) was rapidly injected (less than 3 minutes) through one arm line. Blood samples (3 ml each, in lithium heparin) were obtained at -30', -15', 0', 2', 4', 6', 8', 10', 12', 15', 20', 25', 30', 35', 40', 50', 60', 80', 100', 120', 140', 160' and 180' through the contralateral arm vein. Each sample was immediately centrifuged and plasma was separated. Plasma glucose was measured by the glucose oxidase method (Beckman Glucose Analyzer II, Beckman Instruments, Fullerton, CA, USA). Plasma insulin was assayed by standard radio immunoassay technique. The plasma levels of glucose and insulin obtained at -30', -15' and 0' were averaged to yield the baseline values referred to 0'.

The discrete Single Delay Model

In the development of the discrete SDM, four two-compartment models, describing the variation in time of plasma glucose and plasma insulin concentrations following an IVGTT, have been considered.

For each model the glucose equation includes a second-order linear term describing insulin-dependent glucose uptake, expressed in net terms since it includes changes in liver glucose delivery and changes in glucose uptake, as well as a zero-order term expressing the net balance between a possible constant, insulin-independent fraction of hepatic glucose output and the essentially constant

Table 1: Anthropometric characteristics of the subjects studied (mean \pm SD in 40 subjects).

Gb (mM)	Ib (pM)	Gender n (%)	Age (years)	Height (cm)	BW (kg)	BMI (Kg/m ²)
4.54 \pm 0.51	40.80 \pm 21.88	F 22 (55%) M 18 (45%)	45.25 \pm 16.44	166.10 \pm 8.63	67.53 \pm 10.01	24.36 \pm 2.34

glucose utilization of the brain. A linear term for glucose tissue uptake may or may not be present, and the effect of plasma insulin on glucose kinetics may or may not be delayed.

Variations in plasma insulin concentration depend on the spontaneous decay of insulin and on pancreatic insulin secretion. After the nearly instantaneous first phase insulin secretion, represented in the model by means of the initial condition, a delay term is considered; it represents the pancreatic second phase secretion and formalizes the delay with which the pancreas responds to variations of glucose plasma concentrations.

The details of the four considered models are reported in Table 2. Each model was fitted to the experimentally observed concentrations and for each of the 40 subjects the Akaike value was computed. Models were compared by performing paired t-tests on the computed Akaike scores. The selected model was model A, whose schematic diagram is represented in Figure 1 and whose equations are reported below:

$$\frac{dG(t)}{dt} = -K_{xgl}I(t)G(t) + \frac{T_{gh}}{V_g} \quad (1)$$

Table 2: Tested models and relative average Akaike information Criterion (AIC).

Model	Description	Free parameters	Average AIC
A	Without first order plasma glucose elimination (K_{xg}) and without delay on insulin action (τ_i)	$V_g, I_{\Delta}, \tau_g, K_{xgl}, K_{xi}, \gamma$	383.90
B	With first order plasma glucose elimination (K_{xg}) and without delay on insulin action (τ_i)	$V_g, I_{\Delta}, \tau_g, K_{xgl}, K_{xi}, \gamma, K_{xg}$	386.72
C	Without first order plasma glucose elimination (K_{xg}) and with delay on insulin action (τ_i)	$V_g, I_{\Delta}, \tau_g, K_{xgl}, K_{xi}, \gamma, K_{xg}, \tau_i$	385.95
D	With first order plasma glucose elimination (K_{xg}) and with delay on insulin action (τ_i)	$V_g, I_{\Delta}, \tau_g, K_{xgl}, K_{xi}, \gamma, K_{xg}, K_{xg}, \tau_i$	389.03

The four models studied differ according to the presence or absence of an insulin-independent glucose elimination rate term ($-K_{xg}G$) and according to the presence or absence of an explicit delay in the action of insulin in stimulating tissue glucose uptake ($I(t-\tau_i)$ instead of $I(t)$). The model that does not include either one of these two features was named model A; model B includes the term ($-K_{xg}G$); model C uses $I(t-\tau_i)$ instead of $I(t)$; model D includes both.




Figure 1
Schematic representation of the two-compartment, one-discrete-delay model. V_g and V_i are the distribution volumes respectively for Glucose (G) and Insulin (I). D_g stands for the glucose bolus administered; K_{xgl} is the second-order net elimination rate of glucose per unit of insulin concentration; K_{xi} is the first order elimination rate of insulin; T_{gh} is the net difference between glucose production and glucose elimination; T_{igmax} is the maximal rate of second phase insulin release.

$$G(t) \equiv G_b \forall t \in (-\infty, 0), \quad G(0) = G_b + G_{\Delta}, \quad \text{where } G_{\Delta} = \frac{D_g}{V_g} \quad (1a)$$

$$\frac{dI(t)}{dt} = -K_{xi}I(t) + \frac{T_{igmax}}{V_i} \frac{\left(\frac{G(t-\tau_g)}{G^*}\right)^{\gamma}}{1 + \left(\frac{G(t-\tau_g)}{G^*}\right)^{\gamma}} \quad (2)$$

$$I(0) = I_b + I_{\Delta}G_{\Delta} \quad (2a)$$

The symbols are defined in Table 3. In equation (1) the term $-K_{xgl}(t)G(t)$ represents the net balance between insulin-dependent glucose uptake from peripheral tissues

and insulin-dependent hepatic glucose output (above zero-order, constant hepatic glucose output), whereas the term $\frac{T_{gh}}{V_g}$ represents the net difference between insulin-independent tissue glucose uptake (essentially from the brain) and the constant part of hepatic glucose output. The initial condition $G_b + G_\Delta$ expresses the glucose concentration as the variation with respect to the basal condition, as a consequence of the IV glucose bolus. In the second equation, the first linear term $-K_{xi}I(t)$ represents spontaneous insulin degradation, whereas the second term represents second-phase insulin delivery from the β -cells. Its functional form is consistent with the hypothesis that insulin production is limited, reaching a maximal rate of release T_{igmax}/V_i by way of a Michaelis-Menten dynamics or a sigmoidal shape according to whether the γ value is 1 or greater than 1 respectively. Situations where γ is equal to zero correspond to a lack of response of the pancreas to variations of circulating glucose, while for γ values between zero and 1 the shape of the response resembles a Michaelis-Menten, with a sharper curvature towards the asymptote. The parameter γ expresses therefore the capability of the pancreas to accelerate its insulin

secretion in response to progressively increasing blood glucose concentrations. The initial condition $I_b + I_{\Delta G}$ represents instead the immediate first-phase response of the pancreas to the sudden increment in glucose plasma concentration.

It should be noticed that the form of Equation 1 is by no means new, a similar equation having been discussed, for instance in [33]. On the other hand, as far as we know, the form of Equation 2 is original. In particular, the exponent γ has been introduced to represent the 'acceleration' of pancreatic response with increasing glycemia, and has proved to be necessary for satisfactory model fit during development.

From the steady state condition at baseline it follows that:

$$T_{gh} = K_{xgl}I_bG_bV_g \quad \text{and} \quad T_{igmax} = K_{xi}I_bV_i \left[1 + \left(\frac{G_b}{G^*} \right)^\gamma \right] / \left(\frac{G_b}{G^*} \right)^\gamma$$

An index of insulin sensitivity may be easily derived from this model by applying the same definition as for the Minimal Model [9], i.e.

$$\frac{\partial}{\partial I} \left[-\frac{\partial}{\partial G} \left(\frac{dG}{dt} \right) \right] = \frac{\partial}{\partial I} \left[-\frac{\partial}{\partial G} \left(-K_{xgl}G(t)I(t) + \frac{T_{gh}}{V_g} \right) \right] = K_{xgl} \tag{3}$$

Table 3: Definition of the symbols in the discrete Single Delay Model

Symbol	Units	Definition
t	[min]	time
G(t)	[mM]	glucose plasma concentration at time t
G _b	[mM]	basal (preinjection) plasma glucose concentration
I(t)	[pM]	insulin plasma concentration at time t
I _b	[pM]	basal (preinjection) insulin plasma concentration
K _{xgl}	[min ⁻¹ pM ⁻¹]	net rate of (insulin-dependent) glucose uptake by tissues per pM of plasma insulin concentration
T _{gh}	[mmol min ⁻¹ kgBW ⁻¹]	net balance of the constant fraction of hepatic glucose output (HGO) and insulin-independent zero-order glucose tissue uptake
V _g	[L kgBW ⁻¹]	apparent distribution volume for glucose
D _g	[mmol kgBW ⁻¹]	administered intravenous dose of glucose at time 0
G _Δ	[mM]	theoretical increase in plasma glucose concentration over basal glucose concentration at time zero, after the instantaneous administration and distribution of the I.V. glucose bolus
K _{xi}	[min ⁻¹]	apparent first-order disappearance rate constant for insulin
T _{igmax}	[pmol min ⁻¹ kgBW ⁻¹]	maximal rate of second-phase insulin release; at a glycemia equal to G* there corresponds an insulin secretion equal to T _{igmax} /2
V _i	[L kgBW ⁻¹]	apparent distribution volume for insulin
τ _g	[min]	apparent delay with which the pancreas changes secondary insulin release in response to varying plasma glucose concentrations
γ	[#]	progressivity with which the pancreas reacts to circulating glucose concentrations. If γ were zero, the pancreas would not react to circulating glucose; if γ were 1, the pancreas would respond according to a Michaelis-Menten dynamics, with G* mM as the glucose concentration of half-maximal insulin secretion; if γ were greater than 1, the pancreas would respond according to a sigmoidal function, more and more sharply increasing as γ grows larger and larger
I _{ΔG}	[pM mM ⁻¹]	first-phase insulin concentration increase per mM increase in glucose concentration at time zero due to the injected bolus
G*	[mM]	glycemia at which the insulin secretion rate is half of its maximum




Figure 2
Second-phase pancreatic insulin secretion. Insulin secretion versus plasma glucose concentrations, as computed from the average values of the discrete SDM parameters.

It can be shown [34] that the solutions of the proposed discrete Single-Delay Model for I and G are positive and bounded for all times, and that their time-derivatives are also bounded for all times. Further, the model admits the single (positive-concentration) equilibrium point (G_b, I_b) . The system is also asymptotically locally stable around its equilibrium point. Parameters G^* and V_i are set respectively to 9 mM and $0.25 \text{ L (kgBW)}^{-1}$, so that the set of free parameters of the final model to be estimated is $\{V_g, I_{\Delta G}, \tau_{g'}, K_{xgl}, K_{xi}, \gamma\}$.

Figure 2 shows the shape of the dynamics of insulin release predicted by the model, resulting from the average parameter values estimated on the 40 subjects.

The Minimal Model

The two equations of the standard Minimal Model are written as follows:

$$\frac{dG(t)}{dt} = -[b_1 + X(t)]G(t) + b_1G_b, \quad G(0) = b_0 \quad (4)$$

$$\frac{dX(t)}{dt} = -b_2X(t) + b_3(I(t) - I_b), \quad I(0) = I_b \quad (5)$$

The symbols are defined in Table 4.

The Minimal Model [10] describes the time-course of glucose plasma concentrations, depending upon insulin concentrations and makes use of the variable X , representing the 'Insulin activity in a remote compartment'. While in later years different versions of the Minimal Model appeared [35,36], the original formulation reported above is most widely employed, even in recent research applications [37-44].

Table 4: Definition of the symbols in the Minimal Model

Symbol	Units	Definition
t	[min]	time after the glucose bolus
$G(t)$	[mM]	blood glucose concentration at time t
$X(t)$	[min ⁻¹]	auxiliary function representing insulin-excitabile tissue glucose uptake activity, proportional to insulin concentration in a "distant" compartment
G_b	[mM]	subject's basal (pre-injection) glycemia
I_b	[pM]	subject's basal (pre-injection) insulinemia
b_0	[mM]	theoretical glycemia at time 0 after the instantaneous glucose bolus
b_1	[min ⁻¹]	glucose mass action rate constant, i.e. the insulin-independent rate constant of tissue glucose uptake, "glucose effectiveness"
b_2	[min ⁻¹]	rate constant expressing the spontaneous decrease of tissue glucose uptake ability
b_3	[min ⁻² pM ⁻¹]	insulin-dependent increase in tissue glucose uptake ability, per unit of insulin concentration excess over baseline insulin
$S_1 (b_3/b_2)$	[min ⁻¹ pM ⁻¹]	insulin sensitivity index and represents the capability of tissue to uptake circulating plasma glucose

Statistical Methods

For each subject the four alternative models (A, B, C, D, described in table 2) have been fitted to glucose and insulin plasma concentrations by Generalized Least Squares (GLS, described in Appendix 1) in order to obtain individual regression parameters. All observations on glucose and insulin have been considered in the estimation procedure except for the basal levels. Coefficients of variation (CV) for glucose and insulin were estimated with phase 2 of the GLS algorithm, whereas single-subject CVs for the model parameter estimates were derived from the corresponding variances, obtained from the diagonal elements of the estimated asymptotic variance-covariance matrix of the GLS estimators. The individual-specific regression parameters were then used for population inference.

For the Minimal Model, fitting was performed by means of a Weighted Least Squares (WLS) estimation procedure, considering as weights the inverses of the squares of the expectations and as coefficients of variation 1.5% for glucose and 7% for insulin [9]. Observations on glucose before 8 minutes from the bolus injection, as well as observations on insulin before the first peak were disregarded, as suggested by the proposing Authors [9,10]. A BFGS quasi-Newton algorithm was used for all optimizations [45]. A-posteriori model identifiability was determined by computing the asymptotic coefficient of variation (CV) for the free model parameters: a CV smaller than 52% translates into a standard error of the parameter smaller than $1/1.96$ of its corresponding point estimate and into an asymptotic confidence region of the parameter not including zero.

In order to compare the two models under the same statistical estimation scheme, the Minimal Model was also fitted to observed data points using the same GLS algorithm employed for the SDM.

Results

Delay Model Selection

Each delay model (A, B, C and D) was fitted on data from each one of the experimental subjects and the Akaike Information Criterion (AIC) was computed. Six paired t-tests were performed (A vs. B, A vs. C, A vs. D, B vs. D, C vs. D and B vs. C). Model A had the lowest average on the individual AIC's. All tests were conducted at a level alpha of 0.05 and differences were found to be statistically significant (A vs. B, $P < 0.001$; A vs. C, $P < 0.001$; A vs. D, $P < 0.001$; B vs. D, $P = 0.036$; C vs. D, $P = 0.002$), except for the comparison B vs. C, which was found to be non-significant ($P = 0.191$). The best model under the AIC criterion was therefore model A, which performed significantly better than either model B or C, which in turn performed significantly better than model D.

Model Parameter Estimates

For the discrete SDM the parameter coefficients of variation were derived for each subject from the asymptotic results for GLS estimators. Coefficients of variation for all parameters in all subjects were found to be smaller than 52%, except: for parameter $\tau_{g'}$ which in 5 subjects was estimated to about zero, producing therefore a large CV, and which otherwise exhibited a large CV in 13 other subjects; for parameter γ , in those 3 subjects for whom it was estimated at a value less than 1 as well as for another single subject; and for parameter K_{xi} in 2 subjects.

For the MM, the corresponding standard errors and coefficients of variation (for each parameter and for each subject) were computed by applying standard results for weighted least square estimators, where the coefficients of variation for glucose and insulin were set respectively to 1.5% and 7%. Parameters of the MM were also estimated by means of the same GLS procedure employed for the SDM. However, since for all parameters and individuals the resulting confidence regions were as large as or larger than the corresponding WLS regions, only the more favorable results obtained by WLS were retained for comparison.

Figures 3, 4 and 5 portray three typical subjects with both insulin and glucose concentration observations, as well as predicted time courses based on the discrete SDM and the MM. In order to have a comparison curve for predicted insulin, the original Minimal Model for Insulin secretion [10], fitted by means of the original procedure described by Pacini [46], was employed. For subjects 13 and 27 (figures 3 and 4) the predicted curves are nearly superimposed. For subject 28 (Figure 5), while the MM curve seems closer to the points than that of the SDM, its predicted insulin concentrations are visibly increasing at the end of the observation period (and will be predicted to increase to extremely high levels within a few hours), instead of tending to the equilibrium value I_b . This behavior is common to a few subjects (for subjects 23, 25 and 28 most evidently over 180 minutes) and is consistent with the theoretical results demonstrated in De Gaetano and Arino [31].




Figure 3

Plot for Subject 13. Glucose and Insulin (circles) concentrations versus time together with the predicted time-curves from the SDM (continuous lines) and the MM (dotted lines) for subject 13.




Figure 4
Plot for Subject 27. Glucose and Insulin (circles) concentrations versus time together with the predicted time-curves from the SDM (continuous lines) and the MM (dotted lines) for subject 27.

Figures 6 and 7 report the scatter plots between KxgI and SI. In the first figure all 40 subjects were considered, whereas for the second figure, 5 subjects were discarded: they were those subjects whose indices of insulin-sensitivity SI from the MM were either very small (less than 1.0×10^{-5}) or very large (greater than 1.0×10^2). In all these cases the coefficients of variation of SI were found to be

very large, varying between 1545% and $2.36 \times 10^9\%$. If these extreme-SI subjects are not considered, the scatter plot of figure 7 shows a clear positive correlation between KxgI and SI ($r = 0.93$).

It has been demonstrated that the homeostasis model assessment insulin resistance index HOMA-IR (computed




Figure 5
Plot for Subject 28. Glucose and Insulin (circles) concentrations versus time together with the predicted time-curves from the SDM (continuous lines) and the MM (dotted lines) for subject 28.




Figure 6
S₁ versus K_{xgl} in the whole sample. Scatter plot between the Insulin Sensitivity (S₁) derived from MM and the parameter K_{xgl} over the whole sample of 40 subjects.

as the product of the fasting values of glucose, expressed as mM, and insulin, expressed as μU/mL, divided by the constant 22.5) [47-49], its reciprocal insulin sensitivity index 1/HOMA-IR [50], and the quantitative insulin sensitivity check index QUICKI [51] are useful surrogate indices of insulin resistance because of their high correlation with the index assessed by the euglycemic hyperinsulinemic clamp [11].

The insulin sensitivity index 1/HOMA-IR was therefore compared to the estimated S₁ and K_{xgl} parameter values. Table 5 reports the correlation results. The upper part of the table reports results referred to the whole sample of 40 subjects, while the lower part of the table does not consider the 5 subjects for which the S₁ index could not be reliably computed. The correlation between 1/HOMA-IR and K_{xgl} is about the same in the two analyses and is significant in both, whereas the correlation between 1/




Figure 7
S₁ versus K_{xgl} in the reduced sample. Scatter plot between the Insulin Sensitivity (S₁) derived from MM and the parameter K_{xgl} over the reduced sample of 35 subjects.

Table 5: Correlation between 1/HOMA-IR and the two insulin-sensitivity indices K_{xgl} and S₁

		K _{xgl}	S ₁
1/HOMA-IR full sample	Pearson Correlation	0.588	-0.151
	Sig. (2-tailed)	< 0.001	0.351
	N	40	40
		K _{xgl}	S ₁
1/HOMA-IR reduced sample	Pearson Correlation	0.599	0.569
	Sig. (2-tailed)	< 0.001	< 0.001
	N	35	35

HOMA-IR and S₁ is positive and significant only in the reduced 35-subject sample.

In order to evaluate the performance of the MM also under conditions of arbitrary stabilization of the parameter estimates, WLS data fitting with the Minimal Model was repeated when constraining parameters b₂ and b₃, setting their lower bounds to 10⁻⁵ and 10⁻⁷ respectively. The use of boundaries for parameter values in the optimization process leading to parameter estimation can be a legitimate procedure, especially when starting the optimization, in order to facilitate convergence of the sequence of estimates to the optimum. However, the optimum eventually reached must lie in the interior of the specified region of parameter space in order for it to be a local optimum and for the statistical properties of the resulting estimate to be maintained.

In the case where the optimum lies at one of the boundaries, the gradient of the loss function with respect to the parameter is not zero, the point is not an isolated local optimum and the properties of the considered estimator (Ordinary Least Square, Weighted Least Square or Maximum Likelihood) are lost.

In our case, when arbitrarily delimiting the MM parameters, we did frequently obtain optima at the boundary of the acceptance region. In this case, the predicted curves were as good as in the original 'unconstrained' MM analysis, but parameter estimates sometimes were found to be very different. With this latter procedure 7 subjects exhibited S₁ index values greater than 1 × 10⁻²; the correlation coefficient with the 1/HOMA-IR was 0.173 (P = 0.287) when all 40 subjects were considered and 0.396 (P = 0.023) when these 7 subjects were excluded.

Table 6 reports the sample means of the parameter estimates of the discrete SDM, whereas Table 7 reports the same results for the MM estimated with the standard WLS approach.

It is of interest to note that K_{xgl} and S_I , which measure the same phenomenon, have the same theoretical definition and are computed in the same units, coincide very well in absolute numerical value when the 5 subjects discussed above are not considered ($K_{xgl} = 1.40 \times 10^{-4} \text{ min}^{-1}\text{pM}^{-1}$ vs. $S_I = 1.25 \times 10^{-4} \text{ min}^{-1}\text{pM}^{-1}$). K_{xgl} and S_I , on the other hand, differ markedly if the whole sample is considered ($K_{xgl} = 1.43 \times 10^{-4} \text{ min}^{-1}\text{pM}^{-1}$ vs. $S_I = 30 \text{ min}^{-1} \text{pM}^{-1}$).

Coefficients of variation for glucose and insulin, when considering the discrete SDM, were estimated by GLS to be respectively 19.8% and 31.5%. (for the MM, when adopting the GLS procedure, they were estimated to be respectively 17.5% and 30.9%). Although the estimated values are much larger than those reported in literature [9] (1.5% for glucose and 7% for insulin), they reflect both the variability due to measurement error and the variability

due to actual oscillation of glucose and insulin concentrations in plasma. While these error estimates are rather large, they may be more realistic, in vivo, than simple estimates of the variance of repeated laboratory in-vitro measurements on the same sample.

Discussion

The present work introduces a new model for the interpretation of glucose and insulin concentrations observed during an IVGTT. The model has been tested in a sample of "normal" subjects: these subjects' IVGTTs were selected from a larger group of available IVGTTs on the basis of normality of baseline Glycemia (< 7 mM) and 'normality' of BMI (< 30 Kg m⁻²).

Presentation of the physiological assumptions underlying the discrete Single-Delay Model

The new model was chosen on the basis of the Akaike criterion from a group of four different two-compartment models: all models in the group included first-order insulin elimination kinetics, second-order insulin-dependent net glucose tissue uptake, a zero-order net hepatic glucose output, and progressively increasing but eventually saturating pancreatic insulin secretion in response to rising glucose concentrations. The differences among the four tested models were that, while one model included both an explicit delay in the action of circulating insulin on glucose transport, as well as a term for insulin-independent tissue glucose uptake, one model only included insulin delay, another model only included insulin-independent glucose uptake, and the final model included neither. This final model was chosen because, from a purely numerical point of view, neither the addition of a delay in the insulin action on glucose transport, nor the addition of an insulin-independent, first-order glucose elimination term appeared to improve the model fit to observations.

The delay in the glucose action on pancreatic response, expressed in the discrete SDM by the explicit term τ_g , was found to be necessary if a second-phase insulin response was to produce an evident insulin concentration 'hump'. For this reason, this delay was included in all four models tested in the present work.

It is somewhat surprising that the best model among those studied does not require an explicit delay in insulin action on glucose transport, which had been expressed in the Minimal Model by the 'remote-compartment' insulin activity X [9]. Some reports had in fact indirectly substantiated [52,53] an anatomical basis for this delay: it should be kept in mind, however, that an actual delay in the cellular or molecular action of the hormone is not at all necessary in order to explain the commonly apparent delay in hormone effect, as judged by a perceptible decrease in glucose concentrations. In other words, even if the action of

Table 6: Descriptive Statistics of the parameter estimates for the SDM on the whole sample.

Sample parameter estimates: descriptive statistics						
Parameter	V_g	I_Δ	τ_g	K_{xgl}	k_{xi}	γ
Mean	0.152	41.79	19.271	1.43E-04	0.101	2.464
SD	0.050	20.63	12.156	8.7 E-05	0.079	0.875
CV (%)	32.66	49.38	63.08	60.93	78.00	35.53
SE	0.007	3.263	1.9220	1.38E-05	0.0124	0.1384
CV (%)	5.16	7.81	9.97	9.63	12.33	5.62
min	0.065	11.68	3.58E-6	4.34E-05	0.0314	0.736
max	0.292	90.90	60	4.28E-04	0.480	4.122
Sample correlation matrix of the parameter estimates						
	V_g	I_Δ	τ_g	K_{xgl}	k_{xi}	γ
V_g	1	0.248	0.044	-0.454	-0.353	0.136
I_Δ		1	0.203	-0.529	0.059	0.117
τ_g			1	-0.403	-0.383	-0.185
K_{xgl}				1	0.552	-0.288
k_{xi}					1	0.098
γ						1
σ_f^2	0.039	CV_G	19.75%			
σ_c^2	0.099	CV_I	31.46%			

Table 7: Descriptive Statistics of the parameter estimates from the WLS methods for the MM.

Sample parameter estimates for the 40 Subjects									
Parameter	b ₀	b ₁	b ₂	b ₃	b ₄	b ₅	b ₆	b ₇	S ₁
Values	13.415	0.016	0.061	6.59E-06	0.425	5.091	0.136	618.82	30.00
SD	2.605	0.016	0.107	1.11E-05	1.428	1.362	0.065	311.51	148.48
CV (%)	19.42	98.91	174.90	168.85	335.99	26.75	47.43	50.34	494.99
SE	0.407	0.003	0.017	1.74E-06	0.223	0.213	0.010	48.65	23.19
CV (%)	3.03	15.45	27.32	26.37	52.47	4.18	7.41	7.86	77.30

Sample parameter estimates for the 35 Subjects									
Parameter	b ₀	b ₁	b ₂	b ₃	b ₄	b ₅	b ₆	b ₇	S ₁
Values	13.251	0.013	0.066	7.49E-06	0.222	5.023	0.136	632.869	1.25E-04
SD	2.175	0.012	0.113	1.16E-05	0.372	1.357	0.064	319.523	7.40E-05
CV (%)	16.42	92.92	172.24	155.47	167.22	27.02	47.04	50.49	59.35
SE	0.340	0.002	0.018	1.82E-06	0.058	0.212	0.010	49.901	1.16E-05
CV (%)	2.56	14.51	26.90	24.28	26.12	4.22	7.35	7.88	9.27

Sample correlation matrix of the parameter estimates for the 40 Subjects									
	b ₀	b ₁	b ₂	b ₃	b ₄	b ₅	b ₆	b ₇	
b ₀	1	0.588	-0.264	-0.270	-0.224	0.194	0.023	0.073	
b ₁		1	-0.190	-0.199	0.118	0.289	0.091	0.051	
b ₂			1	0.960	-0.082	-0.165	0.147	-0.126	
b ₃				1	-0.081	-0.185	0.180	-0.209	
b ₄					1	0.506	-0.097	0.020	
b ₅						1	-0.184	0.301	
b ₆							1	0.140	
b ₇								1	

Sample correlation matrix of the parameter estimates for the 35 Subjects									
	b ₀	b ₁	b ₂	b ₃	b ₄	b ₅	b ₆	b ₇	
b ₀	1	0.410	-0.300	-0.314	0.151	0.386	-0.003	0.185	
b ₁		1	-0.155	-0.136	0.539	0.429	0.090	0.203	
b ₂			1	0.968	0.022	-0.145	0.151	-0.153	
b ₃				1	-0.011	-0.174	0.204	-0.249	
b ₄					1	0.694	0.247	0.487	
b ₅						1	-0.123	0.384	
b ₆							1	0.149	
b ₇								1	

the hormone on its target is not retarded, its actual perceptible effect may well exhibit a delay. Thus a mathematical model of the system may correctly show a delayed effect of insulin even in the absence of an explicit term representing retarded action of the hormone. In any case, an explicit representation of this mechanism does not seem necessary to explain the observations in the present series.

Another difference with respect to commonly accepted concepts is the lack of a "glucose effectiveness term", i.e. of a first-order, insulin-independent tissue glucose uptake

rate term. Except for the fact that it has become customary to see this term included in glucose/insulin models, there appears to be no physiological mechanism to support first-order glucose elimination from plasma, when exception is made of glycemia above the renal threshold and when diffusion into a different compartment is discounted. Tissues in the body (except for brain) do not take up glucose irrespective of insulin: brain glucose consumption is relatively constant, and is subsumed, for the purposes of the present model, in the constant net (hepatic) glucose output term. It must be emphasized that none of

the subjects studied exhibited sustained, above-renal-threshold glycemias. It is therefore likely that, even if such a first-order mechanism were indeed present, its explicit representation did not prove indispensable for the acceptable fitting of the present data series. In future analyses it may be necessary to reintroduce insulin action delay or first order insulin-independent glucose uptake or both.

Remarks on decoupled fitting versus single-pass fitting of data points

It is of interest to comment on a widespread conception that interpolated observed data, used in place of theoretically reconstructed curves, are a reliable approximation of the true signal for the purpose of parameter estimation. This approach has been used, for instance, in the original 'decoupling' method of parameter estimation for the MM [46], which we will use simply as an example for illustrating the present remarks.

The strategy of fitting one state variable at a time (while assuming the linearly interpolated, noisy observations of the other state variable to provide the true input function) decouples the regulatory system: the expected feedback effect, of the state variable being fitted onto the other state variable, is disregarded. It happens thus that the estimated parameters are optimal in predicting the observed glucose assuming the erratic observed insulin as the true value of the insulin concentration, but are far from optimal when the expected glucose determines the expected insulin and is then determined by it in its turn. This separate fitting strategy produces sets of estimated parameters such that the expected time course of glucose using the expected time course of insulin as input may differ markedly from both the actual glucose observations and from the expected glucose obtained using the noisy insulin observations as input. In other words, the separate fitting strategy produces parameter values which do not make model predictions of glucose and insulin consistent with each other.

In order to clarify the statement above and to show that the concerns raised are far from purely philosophical, Figure 8 shows four sets of model-reconstructed curves associated with the same data set. In figure 8.a the observed points are fitted with the SDM (one-pass fitting, minimizing errors in glycemias and insulinemias simultaneously) and the resulting SDM-predicted time courses are superimposed. The fitting, with six parameters, is reasonably good and a second-phase insulin secretion "hump" is clearly visible.

In figure 8.b the observed points are fitted with the 'decoupling' Minimal Model based on three equations [46] (two-pass fitting, using interpolated insulinemia as input for the fit of glycemias, then interpolated glycemia

as input for the fit of insulinemia). The predicted curves lie close to the observations (in this set-up eight parameters are free) and second-phase insulin secretion is readily apparent. In figure 8.c the observations are fitted with the same three MM equations, this time using a simultaneous, one-pass procedure. In this way, glycemias and insulinemias are simultaneously predicted from the model and parameters are adjusted to provide the best overall weighted fit. While the predicted curves pass through the observed points, no second-phase insulin secretion hump is visible. In fact, best estimates for the simultaneous three-equation MM parameters never produced a visible second-phase insulin secretion hump in any one of the 40 subjects from the present series. Finally, figure 8.d shows the original observations and the curves obtained when using simultaneously the classical MM parameter estimates. In other words, in figure 8.d the same parameter values obtained in the classical 'decoupling' MM fit of figure 8.b are employed. This time, however, instead of using the recorded noisy observations to provide feedback regulation, the actual predictions of the model are used, so that predicted glycemia influences the prediction of insulinemia and vice-versa. It can be appreciated how, in this case, predictions fail to approximate observations.

If it is required that the identified model be consistent, i.e. that the functional form of the model, together with the estimated parameter values, reproduce the dynamics actually observed, then decoupling the feedback and estimating separately its two arms provides misleading results: while it would seem that the fit is good (Figure 8.b), such good fit actually relies on the specific realization of a chance occurrence of errors in the observations. In this way parameters are obtained which can apparently reproduce features (like in this case the second-phase insulin secretion hump), but can do so only by exploiting that experiment's specific observation errors. When these same parameters are used to model the interaction of predicted glycemias and insulinemias on each other (as in figure 8.d), no such features appear and indeed, even actual data fit is very poor.

Comparison of Insulin Sensitivity determinations from the SDM and the MM

The possibility to reliably estimate an index of insulin-sensitivity is essential to any model which aims at being useful to diabetologists. In the following, we discuss the comparison between the newly-introduced Discrete Single Delay Model, and the Minimal Model in its (to date) uncontroversial formulation, i.e. considering only the two equations (4) and (5), fitted using interpolated insulinemias as forcing function, from which the insulin sensitivity index S_1 is computed. This is the 'standard' MM, being currently used in many experimental applications [37-44].




Figure 8

Comparison between different methods of data fitting. Each figure reports Glucose (white circles) and Insulin (black diamonds) observed concentrations versus time, together with the predicted time-curves (dashed line for Glucose and continuous line for Insulin) using four different methods: the discrete Single Delay Model (figure 8.a); the Minimal Model with its traditional two-pass 'decoupling' estimation method (figure 8.b); the Minimal Model when all parameters are fitted simultaneously (figure 8.c); the Minimal Model when global system behavior (interacting glycemias and insulinemias) is reconstructed from separately estimated (two-pass) parameters (figure 8.d).

By applying the same definition of the Insulin Sensitivity Index to both the discrete SDM and the standard MM, we obtain quantities (the K_{xgl} and the S_I), which have the same units of measurement and, over the restricted subject sample, approximately the same average value and a correlation coefficient of 0.93.

One evident difference between the performances of the discrete SDM and the MM over the 40 subjects considered in this series relates to the stability of estimation, in particular with respect to the insulin sensitivity indices (K_{xgl} for the SDM and S_I for the MM). Whereas in every one of the 40 subjects considered, the estimate of K_{xgl} had a coefficient of variation smaller than 52% (i.e. its 95% asymptotic confidence region excluded zero), in 20 out of 40 'normal' subjects the S_I did not result significantly different from zero.

Correlation between the S_I and the K_{xgl} was poor when considering all 40 subjects, very good when excluding five subjects whose S_I was either very large or very small. Aver-

age values of S_I varied by five orders of magnitude, and correlation with $1/\text{HOMA-IR}$ dropped, when going from the restricted 35-subject sample to the full 40-subject sample. Average values of the K_{xgl} and correlation of the K_{xgl} with $1/\text{HOMA-IR}$ were very similar when using either the full sample or the restricted sample.

Besides the insulin-sensitivity index, all other model parameters were generally identifiable with the discrete SDM and often not identifiable with the MM, pointing to the fact that the MM appears overparametrized with respect to the information available from the standard IVGTT.

It is worth to point out that there is a clear difference between stability and accuracy. In this respect, the result which should be considered is, in our opinion, the correlation with the $1/\text{HOMA-IR}$: when parameter estimates with the MM are numerically stable (when boundary parameter estimates are avoided and in those cases where extreme values are not produced, i.e. the 35-subject

reduced sample), then the MM results correlate well with the other indices (SDM, 1/HOMA-IR), and we should conclude that in this case the three methods deliver more or less accurate estimation of the actual insulin sensitivity of the subjects. When numerical problems in the MM estimation procedure occur (i.e. when considering also the 5 subjects with estimation problems), this correlation, between MM on one hand and SDM or 1/HOMA-IR on the other, is lost (while correlation between SDM and 1/HOMA-IR is always maintained, whether with 40 or with 35 subjects) and extreme S_1 coefficient values are produced. In this case, it would probably be reasonable to think that the two other methods, agreeing with each other and producing plausible numerical estimates, would be more accurate than the MM.

The five poorly identified S_1 's had been singled out as being non-significantly different from zero and either extremely small or extremely large; but in fact the 20 poorly identified S_1 's (with CV > 52%) were distributed over the entire observed S_1 range: this would contradict the simplistic postulation that only those S_1 's are unidentifiable which are too small to be measured (being so low that their confidence interval would include the zero value assuming a constant variance throughout the range), hence that typically the unidentifiable S_1 's correspond to high degrees of insulin resistance.

The five subjects referred to above (subjects 5, 16, 32, 36, 38) had no problems with the SDM (K_{xgl} 's estimated at 1.07×10^{-4} , 9.28×10^{-5} , 1.64×10^{-4} , 1.41×10^{-4} and 3.07×10^{-4} respectively), while their S_1 estimates under the MM (1.53×10^{-6} , $3.03 \times 10^{+2}$, $8.97 \times 10^{+2}$, 1.00×10^{-12} and 1.51×10^{-12}) were extreme because, in order to accurately fit the observations, the values of either the b_2 coefficient or the b_3 coefficient were set essentially to zero (subj 5, $b_3 = 5.37 \times 10^{-8}$; subj 16, $b_2 = 1.86 \times 10^{-9}$; subj 32, $b_2 = 1.14 \times 10^{-9}$; subj 36, $b_3 = 6.35 \times 10^{-14}$; subj 38, $b_2 = 6.63 \times 10^{-14}$).

This happens because, in these five subjects in particular, observed insulinemias display an erratic behavior. Since the MM does not use a model for insulinemia, but uses interpolated (error-containing) observations on insulinemia to drive the glycemia model, parameters get estimated so as to explain observed glycemias on the basis of erratic insulinemias, and sometimes these parameters will be off-scale. The same may occur, due to relative overparametrization, if it is the glycemias which exhibit correlated errors or large oscillations, even in the presence of smoothly varying observed insulinemias.

The occurrence of "zero- S_1 " values (S_1 values with very low point estimation) has long been a recognized problem with the MM. For instance, in 1997, Ni et al. [54] affirmed that "... the occurrence of S_1 values indistinguishable from

zero ("zero- S_1 ") is not negligible in large clinical studies". This was supposed to be due to inaccurate one-compartment modelling of the glucose kinetics, and to be resolved by the use of a more complex two-compartment model (which would on the other hand have introduced more parameters in the estimation process). In the present series of non-obese subjects, while estimation with the MM gave rise to 3 out of 40 zero- S_1 cases, the S_1 was in fact not significantly different from zero in half of the subjects, while the SDM produced insulin sensitivity coefficients K_{xgl} which were significantly different from zero in all subjects, (with a minimum K_{xgl} of 4.34×10^{-5}). It is therefore possible that overparametrization of the MM plays a greater role than the level of approximation (with a single rather than a double compartment for glucose) in the production of "zero- S_1 " estimates.

We finally note that the I_{AG} parameter from the SDM has the same meaning as the dynamic responsivity index Φ_d used by Campioni et al. [55] to characterize the secretion rate of insulin from the promptly releasable pool (assuming it proportional to the actual glucose concentration reached).

Conclusion

The SDM has been designed for simultaneous fitting to glucose and insulin concentrations, and has been proven to have mathematically consistent solutions, admitting the fasting state as its single equilibrium point and converging back to it from the perturbed state. The sigmoidal shape of pancreatic insulin secretion in response to increasing glucose concentrations agrees with plausible physiology, since pancreatic ability to secrete insulin is limited.

In the present work it has been shown that, in 20 out of 40 healthy volunteers, while the standard Minimal Model fails to assess reliably the S_1 index, the SDM provides a precise estimate of insulin sensitivity. The present work therefore shows that the statistical, mathematical and physiological design features of the SDM actually translate, when the model is applied to data, into meaningful, robust estimates of insulin sensitivity from the standard IVGTT.

Future work in the evaluation of this model will entail testing it in samples of subjects with high prevalence of insulin resistance. Free software for fitting the SDM to a set of IVGTT data is available from the webpage of the CNR IASI Biomathematics Lab [56].

Appendix

To obtain subject-specific model parameters and population estimates on the SDM the GLS method was used. GLS is a two-stage method:

(1) at first individual estimates β_i^* for each subject i ($i = 1, \dots, 40$) are obtained;

(2) then the estimates β_i^* are used to construct the population estimates.

When observations are taken at different times from several subjects, it is important to take into account in the modeling procedure two sources of variability: random variation among measurements within a given individual and random variation among individuals. To accommodate these two different variance components a hierarchical statistical model was built:

Stage 1 (intra-individual variation)

given the model:

$$y_i = f_i(\beta_i) + e_i$$

$$E(e_i|\beta_i) = 0 \text{ Cov}(e_i|\beta_i) = R(\beta_i, \xi)$$

where $E(y_i) = f_i$ with f_i representing the numerical solution of SDM for subject i , the variability within subject i is expressed by means of the functional form of $R(\beta_i, \xi)$, where the additional intra-individual covariance parameter vector ξ is the same across the individuals. Denoting with G and I respectively the state variable Glucose and the state variable Insulin, the variance-covariance matrix R in the present application has the structure of a block-diagonal matrix:

$$R_i = \begin{bmatrix} R_G & 0 \\ 0 & R_I \end{bmatrix}$$

where

$$R_i = \begin{bmatrix} \sigma_G^2 f_{iG}^2(\beta_i, t_{i1}) & \dots & 0 \\ \dots & \dots & \dots \\ 0 & \dots & \sigma_I^2 f_{iI}^2(\beta_i, t_{in_i}) \end{bmatrix}$$

The parameters σ_G^2 and σ_I^2 , which have to be estimated, are the squares of the coefficients of variation respectively for glucose and insulin.

Stage 2 (inter-individual variation)

In the second stage of the hierarchical model the variation among individuals (due for example to gender, age, treatment group or simply to biological variability among different individuals), is taken into account by means of a statistical model for the subject structural parameters β_i . In this work the simplest case of a linear model has been considered:

$$\beta_i = \beta + b_i, \quad b_i \sim N(0, D)$$

where β is the vector of the fixed effects or the vector of the population parameters, whereas b_i is the vector of the random effects for the i -th individual.

The Standard Two Stage method (STS) proceeds according to the following scheme:

STAGE 1

(1) In m separate estimation procedures (where m is the total number of subjects), obtain preliminary estimates $\beta_i^{(p)}$ for each individual i , $i = 1, \dots, m$ ($m = 40$).

(2) Use residuals from these preliminary fits to estimate $\xi = (\sigma_G^2, \sigma_I^2)$ minimizing the following function:

$$PL = \sum_{i=1}^m \log |R_i(\beta_i^{(p)}, \xi)| + [y_i - f_i(\beta_i^{(p)})]^T R_i^{-1}(\beta_i^{(p)}, \xi) [y_i - f_i(\beta_i^{(p)})]$$

(3) Form estimated weight matrices based on the estimated parameters $\hat{\xi}$ and $\beta_i^{(p)}$:

$$\hat{R}_i(\beta_i^{(p)}, \hat{\xi})$$

(4) Using the estimated weight matrices from step (3), re-estimate the β_i by means of m minimizations: for each individual i , $i = 1, \dots, m$ minimize the following quantity

$$[y_i - f_i(\beta_i)]^T R^{-1}(\beta_i^{(p)}, \xi) [y_i - f_i(\beta_i)]$$

The resulting estimates can be treated as preliminary estimates and it is possible to return to point (2). The algorithm should be iterated at least once and for each individual i the final estimates are denoted with β_{iGLS} .

STAGE 2

In this stage it is assumed that the estimates β_{iGLS} are treated as they were known. So the population estimates of the vector β and of the variance-covariance matrix D are

given by the sample mean and the sample variance-covariance matrix:

$$\hat{\beta} = \frac{1}{m} \sum_{i=1}^m \hat{\beta}_{i_{\text{GLS}}} \quad \text{and} \quad \hat{D} = \frac{1}{(m-1)} \sum_{i=1}^m (\hat{\beta}_{i_{\text{GLS}}} - \hat{\beta})^T (\hat{\beta}_{i_{\text{GLS}}} - \hat{\beta}).$$

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

SP: mathematical modelling, statistical analysis, drafting of the manuscript;

PP: mathematical modeling;

ADG: mathematical modeling, drafting of the manuscript;

All authors read and approved the final manuscript.

Acknowledgements

This work has been conducted in the spirit and following the ideas and encouragement of the late Prof. Ovide Arino, whose untimely disappearance was a terrible loss for his disciples. The authors wish to thank Prof. Geltrude Mingrone for having made the original IVGTT data available, and Prof. Alessandro Bertuzzi for the very valuable comments. This work has been partially supported by FIRB project RBAU01K7M2 from the Italian Ministry of Instruction, University and Research.

References

1. DeFronzo RA: **Insulin resistance, hyperinsulinemia, and coronary artery disease: a complex metabolic web.** *J Cardiovasc Pharmacol* 1992, **20 Suppl 11**:S1-16.
2. DeFronzo RA, Ferrannini E: **Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.** *Diabetes Care* 1991, **14**:173-194.
3. Hutley L, Prins JB: **Fat as an endocrine organ: relationship to the metabolic syndrome.** *Am J Med Sci* 2005, **330**:280-289.
4. Kaur H, Hyder ML, Poston WS: **Childhood overweight: an expanding problem.** *Treat Endocrinol* 2003, **2**:375-388.
5. Muhammad S: **Epidemiology of diabetes and obesity in the United States.** *Compend Contin Educ Dent* 2004, **25**:195-8, 200, 202.
6. Henry RR: **Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.** *Clin Ther* 2003, **25 Suppl B**:B47-B63.
7. Nambi V, Hoogwerf RJ, Sprecher DL: **A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.** *Cleve Clin J Med* 2002, **69**:985-989.
8. Escalante-Pulido M, Escalante-Herrera A, Milke-Najar ME, Alpizar-Salazar M: **Effects of weight loss on insulin secretion and in vivo insulin sensitivity in obese diabetic and non-diabetic subjects.** *Diabetes Nutr Metab* 2003, **16**:277-283.
9. Bergman RN, Ider YZ, Bowden CR, Cobelli C: **Quantitative estimation of insulin sensitivity.** *Am J Physiol* 1979, **236**:E667-E677.
10. Toffolo G, Bergman RN, Fingood DT, Bowden CR, Cobelli C: **Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog.** *Diabetes* 1980, **29**:979-990.
11. DeFronzo RA, Tobin JD, Andres R: **Glucose clamp technique: a method for quantifying insulin secretion and resistance.** *Am J Physiol* 1979, **237**:E214-E223.
12. Bolie VW: **Coefficients of normal blood glucose regulation.** *J Appl Physiol* 1961, **16**:783-788.
13. Ackerman E, Gatewood LC, Rosevear JW, Molnar GD: **Model studies of blood-glucose regulation.** *Bull Math Biophys* 1965, **27**:Suppl:21-Suppl:37.
14. Subba Rao G, Bajaj JS, Subba Rao J: **A mathematical model for insulin kinetics. II. Extension of the model to include response to oral glucose administration and application to insulin-dependent diabetes mellitus (IDDM).** *J Theor Biol* 1990, **142**:473-483.
15. Turner RC, Rudenski AS, Matthews DR, Levy JC, O'Rahilly SP, Hosker JP: **Application of structural model of glucose-insulin relations to assess beta-cell function and insulin sensitivity.** *Horm Metab Res Suppl* 1990, **24**:66-71.
16. Proietto J: **Estimation of glucose kinetics following an oral glucose load. Methods and applications.** *Horm Metab Res Suppl* 1990, **24**:25-30.
17. Nomura M, Shichiri M, Kawamori R, Yamasaki Y, Iwama N, Abe H: **A mathematical insulin-secretion model and its validation in isolated rat pancreatic islets perfusion.** *Comput Biomed Res* 1984, **17**:570-579.
18. Sluiter WJ, Erkelens DW, Terpstra P, Reitsma WD, Doorenbos H: **Glucose tolerance and insulin release, a mathematical approach. II. Approximation of the peripheral insulin resistance after oral glucose loading.** *Diabetes* 1976, **25**:245-249.
19. Gatewood LC, Ackerman E, Rosevear JW, Molnar GD, Burns TW: **Tests of a mathematical model of the blood-glucose regulatory system.** *Comput Biomed Res* 1968, **2**:1-14.
20. Ceresa F, Ghemi F, Martini PF, Martino P, Segre G, Vitelli A: **Control of blood glucose in normal and in diabetic subjects. Studies by compartmental analysis and digital computer technics.** *Diabetes* 1968, **17**:570-578.
21. Jansson L, Lindskog L, Norden NE: **Diagnostic value of the oral glucose tolerance test evaluated with a mathematical model.** *Comput Biomed Res* 1980, **13**:512-521.
22. O'Connor MD, Landahl H, Grodsky GM: **Comparison of storage- and signal-limited models of pancreatic insulin secretion.** *Am J Physiol* 1980, **238**:R378-R389.
23. Sturis J, Polonsky KS, Mosekilde E, Van Cauter E: **Computer model for mechanisms underlying ultradian oscillations of insulin and glucose.** *Am J Physiol* 1991, **260**:E801-E809.
24. Topp B, Promislow K, deVries G, Miura RM, Finegood DT: **A model of beta-cell mass, insulin, and glucose kinetics: pathways to diabetes.** *J Theor Biol* 2000, **206**:605-619.
25. Tolic IM, Mosekilde E, Sturis J: **Modeling the insulin-glucose feedback system: the significance of pulsatile insulin secretion.** *J Theor Biol* 2000, **207**:361-375.
26. Lenbury Y, Ruktamatakul S, Amornsamarnkul S: **Modeling insulin kinetics: responses to a single oral glucose administration or ambulatory-fed conditions.** *Biosystems* 2001, **59**:15-25.
27. Makroglou A, J. L, Kuang Y: **Mathematical models and software tools for the glucose-insulin regulatory system and diabetes: an overview.** *Applied Numerical Mathematics* 2005.
28. Bennett L, S. G: **Asymptotic properties of a delay differential equation model for the interaction of glucose with plasma and interstitial insulin.** *Applied Mathematics and Computation* 2004, **151**:189-207.
29. Prager R, Wallace P, Olefsky JM: **In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects.** *J Clin Invest* 1986, **78**:472-481.
30. Shapiro ET, Tillil H, Polonsky KS, Fang VS, Rubenstein AH, Van Cauter E: **Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose.** *J Clin Endocrinol Metab* 1988, **67**:307-314.
31. De Gaetano A, Arino O: **Mathematical modelling of the intravenous glucose tolerance test.** *J Math Biol* 2000, **40**:136-168.
32. Mukhopadhyay A, De Gaetano A, Arino O: **Modelling the Intra-Venous Glucose Tolerance Test: a global study for a single-distributed-delay model.** *Discr Cont Dyn Syst B* 2004.
33. Millsaps K, Pohlhause K: **A Mathematical Model for Glucose-Insulin interaction.** *Math Biosci* 1975, **23**:237-251.
34. Palumbo P, Panunzi S, De Gaetano A: **Qualitative behavior of a family of delay-differential models of the glucose-insulin system.** *Discrete and Continuous Dynamical Systems - Series B* 2007, **7**:399-424.
35. Caumo A, Giacca A, Morgese M, Pozza G, Micossi P, Cobelli C: **Minimal models of glucose disappearance: lessons from the labelled IVGTT.** *Diabet Med* 1991, **8**:822-832.

36. Callegari T, Caumo A, Cobelli C: **Bayesian two-compartment and classic single-compartment minimal models: comparison on insulin modified IVGTT and effect of experiment reduction.** *IEEE Trans Biomed Eng* 2003, **50**:1301-1309.
37. Pedrini MT, Niederwanger A, Kranebitter M, Tautermann C, Ciardi C, Tatarczyk T, Patsch JR: **Postprandial lipaemia induces an acute decrease of insulin sensitivity in healthy men independently of plasma NEFA levels.** *Diabetologia* 2006, **49**:1612-1618.
38. Penesova A, Rovensky J, Zlnay M, Dedik L, Radikova Z, Koska J, Vigas M, Imrich R: **Attenuated insulin response and normal insulin sensitivity in lean patients with ankylosing spondylitis.** *International Journal of Clinical Pharmacology Research* 2005, **25**:107-114.
39. Hsieh CH, Hung J, He CT, Lee CH, Hung SC, Wang YK, Kuo SW, Pei D: **The capability of glucose toxicity on severe type 2 diabetes.** *Endocrine Research* 2005, **31**:149-158.
40. Ranganathan G, Unal R, Pokrovskaya I, Yao-Borengasser A, Phanavanh B, Lecka-Czernik B, Rasouli N, Kern PA: **The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.** *Journal of Lipid Research* 2006, **47**:2444-2450.
41. Fernandez-Real JM, Lopez-Bermejo A, Castro A, Casamitjana R, Ricart W: **Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects.** *Journal of Clinical Endocrinology and Metabolism* 2006, **91**:3337-3343.
42. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC: **Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: A frequently sampled intravenous glucose tolerance test and minimal model analysis.** *Journal of Clinical Psychiatry* 2006, **67**:789-797.
43. Cagnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A: **Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome.** *Contraception* 2006, **73**:348-351.
44. Treiber KH, Boston RC, Kronfeld DS, Staniar WB, Harris PA: **Insulin resistance and compensation in Thoroughbred weanlings adapted to high-glycemic meals.** *Journal of Animal Science* 2005, **83**:2357-2364.
45. Press WH, Flannery BP, Teukolsky SA, Vetterling WT: *Numerical recipes in C. The art of scientific computing* 2nd edition. Cambridge, Cambridge University Press; 1994.
46. Pacini G, Bergman RN: **MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsiveness from the frequently sampled intravenous glucose tolerance test.** *Comput Methods Programs Biomed* 1986, **23**:113-122.
47. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: **Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.** *Diabetologia* 1985, **28**:412-419.
48. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H: **Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.** *Diabetes Care* 1999, **22**:818-822.
49. Bonora E, Targher G, Alberiche M, Bonadonna R, Saggiani F, Zenere MB, Monauni T, Muggero M: **Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.** *Diabetes Care* 2000, **23**:57-63.
50. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Shoji T, Okuno Y, Nishizawa Y: **Quantitative Insulin Sensitivity Check Index and the Reciprocal Index of Homeostasis Model Assessment in Normal Range Weight and Moderately Obese Type 2 Diabetic Patients.** *Diabetes Care* 2003, **26**:2426-2432.
51. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: **Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.** *J Clin Endocrinol Metab* 2000, **85**:2402-2410.
52. Bergman RN: **Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach.** *Diabetes* 1989, **38**:1512-1527.
53. Bergman RN, Yang YJ, Hope ID, Ader M: **The role of the transcapillary insulin transport in the efficiency of insulin action: studies with glucose clamps and the minimal model.** *Horm Metab Res Suppl* 1990, **24**:49-56.
54. Ni TC, Ader M, Bergman EN: **Reassessment of glucose effectiveness and insulin sensitivity from minimal model analysis: a theoretical evaluation of the single-compartment glucose distribution assumption.** *Diabetes* 1997, **46**:1813-1821.
55. Campioni M, Toffolo G, Shuster LT, Service FJ, Rizza RA, Cobelli C: **Incretin effect potentiates b-cell responsiveness to glucose as well as to its rate of change: OGTT and matched intravenous study.** *Am J Physiol Endocrinol Metab* 2007, **292**:E54-E60.
56. **WebService Model fitting** 2007 [<http://www.biomatematica.it/bibif/bibif.html>].

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

